These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


372 related items for PubMed ID: 12593726

  • 1. Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine.
    Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H, Mann K, Basedow Study Group.
    Thyroid; 2002 Dec; 12(12):1119-28. PubMed ID: 12593726
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
    Brokken LJ, Wiersinga WM, Prummel MF.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
    [Abstract] [Full Text] [Related]

  • 7. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 8. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
    Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M, Sanmartí A.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2410-3. PubMed ID: 9253309
    [Abstract] [Full Text] [Related]

  • 9. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P, Berman DC, Andersen S, Bülow Pedersen I.
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [Abstract] [Full Text] [Related]

  • 10. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A.
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [Abstract] [Full Text] [Related]

  • 11. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X, Shi B, Li H.
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [Abstract] [Full Text] [Related]

  • 12. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T.
    N Engl J Med; 1991 Apr 04; 324(14):947-53. PubMed ID: 1900575
    [Abstract] [Full Text] [Related]

  • 13. [Drug treatment of immune hyperthyroidism (Basedow disease). Patient selection, long-term follow-up and prevention of recurrence].
    Quadbeck B, Hörmann R, Janssen OE, Mann K.
    Internist (Berl); 2003 Apr 04; 44(4):440-8. PubMed ID: 12914401
    [Abstract] [Full Text] [Related]

  • 14. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease.
    Fukao A, Takamatsu J, Murakami Y, Sakane S, Miyauchi A, Kuma K, Hayashi S, Hanafusa T.
    Clin Endocrinol (Oxf); 2003 May 04; 58(5):550-5. PubMed ID: 12699435
    [Abstract] [Full Text] [Related]

  • 15. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H.
    Clin Endocrinol (Oxf); 1998 Oct 04; 49(4):451-7. PubMed ID: 9876342
    [Abstract] [Full Text] [Related]

  • 16. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M, Castagnone D, Rivolta R, Meroni L, Pappalettera M, Cantalamessa L.
    Thyroid; 1997 Dec 04; 7(6):823-8. PubMed ID: 9459623
    [Abstract] [Full Text] [Related]

  • 17. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS, Zwicker H, Abbott EC, Douglas R, Givner ML, Gupta MK, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE.
    J Clin Endocrinol Metab; 1996 Sep 04; 81(9):3283-8. PubMed ID: 8784084
    [Abstract] [Full Text] [Related]

  • 18. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee MS, Lee MK, Kim KW, Chung JH.
    Thyroid; 2006 Dec 04; 16(12):1251-7. PubMed ID: 17199435
    [Abstract] [Full Text] [Related]

  • 19. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B, Hoermann R, Hahn S, Roggenbuck U, Mann K, Janssen OE.
    Horm Metab Res; 2005 Dec 04; 37(12):745-50. PubMed ID: 16372228
    [Abstract] [Full Text] [Related]

  • 20. Successful use of iodine and levothyroxine to treat Graves' disease in a pregnant patient with allergy to antithyroid drugs and high thyrotropin-binding inhibitor immunoglobulin after radioiodine therapy.
    Kubota S, Ohye H, Sasaki I, Nishihara E, Kudo T, Fukata S, Amino N, Kuma K, Mitsuda N, Miyauchi A.
    Thyroid; 2005 Dec 04; 15(12):1373-6. PubMed ID: 16405411
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 19.